Netherlands-headquartered Qiagen has signed a definitive agreement to acquire Israel-based Genoox, a provider of artificial intelligence (AI)-powered software that enables clinical labs to scale and accelerate the processing of complex genetic tests.
The acquisition adds Franklin, Genoox’s flagship cloud-based community platform, to the Qiagen Digital Insights (QDI) portfolio, strengthening Qiagen’s leadership in genetic interpretation for clinical genomics applications.
Franklin empowers labs to analyse next-generation sequencing (NGS) data – from targeted gene panels to whole exome and genome sequencing (WES/WGS) - and delivers real-time, AI-driven insights to support clinical decision-making. Applications range from diagnosing genetic disorders and informing cancer treatments to supporting family planning decisions.
The platform is currently used by more than 4,000 healthcare organizations in over 50 countries and has powered more than 750,000 case interpretations to date.
Qiagen has acquired Genoox for $70 million in cash and eligible for additional milestone payments of up to $10 million. The acquisition is expected to generate approximately $5 million of sales in 2025 for QIAGEN.
